Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice

• Main Authors: Luciana de Sá Quirino-Makarczyk, Maria de Fátima Sainz Ugarte, Bruna Viana Vieira, Sérgio Kniggendorf, Caio Vinicius Saito Regatieri
• Format: Article
• Language: English
• Published: BMC 2020-05-01
• Series: International Journal of Retina and Vitreous
• Subjects: Aflibercept; Ranibizumab; Age-related macular degeneration; Vascular endothelial growth factor
• Online Access: http://link.springer.com/article/10.1186/s40942-020-00212-5

Abstract Background To evaluate the change in best corrected visual acuity (VA) and central macular thickness (CMT) following treatment with intravitreal aflibercept (AFL) in patients poorly responders or non responders to ranibizumab (RBZ). Methods Charts of patients injected with RBZ from January 2016 to December 2018 (548 cases) due to neovascular age-related macular degeneration (nAMD) were reviewed. Fifty-six cases met our criteria for poor responders to RBZ (CMT decreased between 5 and 15% over treatment) or for non responders to RBZ (CMT decreased less than 5% or increased over treatment). Results After the third AFL injection, CMT decreased from 384.38 ± 123.20 μm to 296.18 ± 70.52 μm in the non-responder group and from 320.00 ± 82.05 μm to 282.27 ± 56.86 μm in the poor responder group. Although decrease in macular thickness was overall achieved 3 months after switching to AFL, it was not translated in VA improvement. Conclusions it was observed that nAMD patients classified as RBZ non-responders tend to respond better to AFL than RBZ poor-responders anatomically, without correspondent improvement in VA.